Portal de investigación
Inflammatory bowel disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVID-Surg)
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Rottoli, M
- Pellino, G
- Tanzanu, M
- Baldi, C
- Frontali, A
- Carvello, M
- Foppa, C
- Kontovounisios, C
- Tekkis, P
- Colombo, F
- Danelli, P
- Celentano, V
- Spinelli, A
- Panis, Y
- Sampietro, GM
- Poggioli, G
Grupos
Abstract
Outcomes of inflammatory bowel disease (IBD) patients requiring surgery during the outbreak of Coronavirus disease 19 (COVID-19) are unknown. Aim of this study was to analyse the outcomes depending on the COVID-19 status of the centre. Patients undergoing surgery in six COVID-19 treatment and one COVID-free hospitals (five countries) during the first COVID-19 peak were included. Variables associated with risk of moderate-to-severe complications were identified using logistic regression analysis. A total of 91 patients with Crohn's disease (54, 59.3%) or ulcerative colitis (37, 40.7%), 66 (72.5%) had surgery in one of the COVID-19-treatment hospitals, while 25 (27.5%) in the COVID-19-free centre. More COVID-19-treatment patients required urgent surgery (48.4% vs. 24%, p = 0.035), did not discontinue biologic therapy (15.1% vs. 0%, p = 0.039), underwent surgery without a SARS-CoV-2 test (19.7% vs. 0%, p = 0.0033), and required intensive care admission (10.6% vs. 0%, p = 0.032). Three patients (4.6%) had a SARS-CoV-2 infection postoperatively. Postoperative complications were associated with the use of steroids at surgery (Odds ratio [OR] = 4.10, 95% CI 1.14-15.3, p = 0.03), presence of comorbidities (OR = 3.33, 95% CI 1.08-11, p = 0.035), and Crohn's disease (vs. ulcerative colitis, OR = 3.82, 95% CI 1.14-15.4, p = 0.028). IBD patients can undergo surgery regardless of the COVID-19 status of the referral centre. The risk of SARS-CoV-2 infection should be taken into account.
Datos de la publicación
- ISSN/ISSNe:
- 2038-131X, 2038-3312
- Tipo:
- Article
- Páginas:
- 1811-1818
- Factor de Impacto:
- 0,577 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Updates in Surgery Springer Verlag
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- Inflammatory bowel disease; Surgery; COVID-19
Proyectos asociados
WIBEC. WIRELESS IN-BODY ENVIRONMENT COMMUNICATIONS.
Investigador Principal: VICENTE PONS BELTRÁN
675353 . COMISION EUROPEA . 2016
MODELOS DE HÍGADO AISLADO PERFUNDIDO PARA EL RESCATE DE ÓRGANOS Y TRASLACIÓN DE LA TERAPIA GÉNICA EN EL TRASPLANTE: ESCENARIOS HUMANO "EX VIVO" Y PORCINO "IN VIVO"
Investigador Principal: RAFAEL LÓPEZ ANDÚJAR
2017_0270_CRC_LOPEZ . FUNDACION MUTUA MADRILEÑA . 2017
"TIMing Evaluation of Stoma closure” Cierre precoz vs tardío del estoma derivativo tras cirugía de cáncer de recto.
Investigador Principal: MATTEO FRASSON
2018_0078_CRC_FRASSON . ASOCIACIÓN ESPAÑOLA DE COLOPROCTOLOGÍA (AECP) . 2018
Terápia génica no-viral con 1L 10 para el tratamiento de la enfermedad inflamatoria intestinal. Estudio preliminar con piezas de cólon humano ex vivo.
Investigador Principal: MATTEO FRASSON
PI18/01658 . INSTITUTO DE SALUD CARLOS III . 2019
INDIVIDUALIZED PERIOPERATIVE HEMODYNAMIC GOAL-DIRECTED THERAPY IN MAJOR ABDOMINAL SURGERY (IPEGASUS-TRIAL).
Investigador Principal: ÓSCAR DÍAZ CAMBRONERO
IPEGASUS . 2017
MU OPIOID RECEPTOR 1 (MOR-1) EXPRESSION IN COLORECTAL CANCER AND DISEASE-FREE SURVIVAL RELATIONSHIP (MOROCCO). FIVE-YEAR FOLLOW-UP.
Investigador Principal: ÓSCAR DÍAZ CAMBRONERO
ODC-MOR-2018-01
MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS (MASC).
Investigador Principal: MATTEO FRASSON
MFR-CIC-2018-01 . 2019
UTILIDAD DE UNA MALLA SUPRAAPONEURÓTICA COMO PROFILAXIS DE LA EVENTRACIÓN DE LINEA MEDIA TRAS RESECCIÓN ONCOLOGICA COLORRECTAL. ESTUDIO PROSPECTIVO ALEATORIZADO MONOCÉNTRICO.
Investigador Principal: MATTEO FRASSON
PEACE . 2016
EVALUACION DE LA EFICACIA Y SEGURIDAD DEL SELLANTE HEMOSTATICO HEMOPATCH EN LA REDUCCION DE LA INCIDENCIA DE LA HEMORRAGIA Y LA FISTULA BILIAR TRAS LA CIRUGIA DE RESECCION HEPATICA PROGRAMADA.
Investigador Principal: RAFAEL LÓPEZ ANDÚJAR
HEMOPATCH . 2016
MINIMALLY INVASIVE RIGHT COLECTOMY ANASTOMOSIS STUDY (MIRCAST).
Investigador Principal: MATTEO FRASSON
MIRCAST . 2019
ESTUDIO MULTICÉNTRICO PROSPECTIVO, CONTROLADO, ALEATORIZADO DE NO INFERIORIDAD SOBRE EL MANEJO DE LA SONDA VESICAL EN CIRUGÍA DE COLON.
Investigador Principal: MÓNICA MILLÁN SCHEIDING
CR-VESICATH . 2021
Cita
Rottoli M,Pellino G,Tanzanu M,Baldi C,Frontali A,Carvello M,Foppa C,Kontovounisios C,Tekkis P,Colombo F,Sancho J,Frasson M,Danelli P,Celentano V,Spinelli A,Panis Y,Sampietro GM,Poggioli G. Inflammatory bowel disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVID-Surg). Updates Surg. 2021. 73. (5):p. 1811-1818. IF:2,692. (2).